Alumis resumes decline a day after first positive session post IPO
09/07/2024 15:44
** Shares of biopharmaceutical firm Alumis ALMS.O dip 1.3%
a day after their first gain since lackluster initial public
offering last month
** Company is developing oral therapies to address immune
dysfunction
** ALMS is among a few companies that failed to lure
investors, as IPO market recovery falters
** As of last close, ALMS is 20% off its IPO price
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial